BGB-11417 (BCL-2 inhibitor for myeloid malignancies)

Current understanding

To be populated as evidence accumulates.

2026-09-11 — A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML: cross-connection with lp-108-azacitidine-combination: Both are next-generation BCL-2 inhibitors being developed as alternatives/successors to venetoclax in myeloid malignancies. (novelty: 3)
2026-04-23 — A Study of BGB-11417 in Participants With Myeloid Malignancies: Phase 1/2 trial (NCT-listed) is evaluating BGB-11417 as monotherapy and in combination with azacitidine in AML, MDS, and MDS/MPN overlap, with primary endpoints of safety, tolerability, and RP2D plus preliminary efficacy (early trial data, no readout yet). (novelty: 3)